Dose Optimization Study of Idelalisib in Follicular Lymphoma.

Trial Profile

Dose Optimization Study of Idelalisib in Follicular Lymphoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Jun 2021 to 1 May 2023.
    • 17 Mar 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2021.
    • 22 Sep 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top